0001209191-15-009892.txt : 20150205
0001209191-15-009892.hdr.sgml : 20150205
20150205171220
ACCESSION NUMBER: 0001209191-15-009892
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150203
FILED AS OF DATE: 20150205
DATE AS OF CHANGE: 20150205
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LEIDEN JEFFREY M
CENTRAL INDEX KEY: 0001242825
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 15581055
MAIL ADDRESS:
STREET 1: 40 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-02-03
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001242825
LEIDEN JEFFREY M
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
1
1
0
0
CEO & President
Common Stock
2015-02-03
4
A
0
64500
0.01
A
282177
D
Common Stock
440
I
401(k)
Stock Option (right to buy)
109.14
2015-02-03
4
A
0
213000
0.00
A
2025-02-02
Common Stock
213000
213000
D
Performance-based restricted stock award that will vest as to (i) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales in the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results of a clinical trial establishing proof-of-concept for a next generation CFTR corrector and (ii) 50% of the shares on the earlier to occur of (a) the attainment of a specified level of net product sales outside of the United States of lumacaftor in combination with ivacaftor over four calendar quarters and (b) the announcement of the results from a successful pivotal clinical trial for a non-cystic fibrosis drug candidate sufficient to support the filing of an NDA.
The option vests in 16 quarterly installments from 02/03/2015.
Omar White, Attorney-In-Fact
2015-02-05